SAN DIEGOT Allele Biotechnology & Pharmaceuticals Inc. has received issuance notices from the U.S. Patent and Trademark Office for its first batch of patents covering the derivation of induced pluripotent stem cells (iPSCs). Allele’s proprietary technology uses only messenger RNA (mRNA) to reprogram human or other primate cells, avoiding many operational complications that other methods […]
SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced that it sent a letter to the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding misstatements in the S-1 Registration Statement filed by Twist Bioscience Corp. The letter informs the SEC that “Twist’s S-1 Fails to Disclose that Twist CEO […]
This is the 31st DART-related patent for IonSense and further strengthens its position in ambient ionization. The invention enables high-throughput screening of drugs of abuse. SAUGUS, Mass. — IonSense, Inc. has announced that the U.S. Patent and Trademark Office has issued a patent related to its Direct Analysis in Real Time (DART®) mass spectrometry technology. […]
WAKEFIELD, Mass.–Genetics Research LLC, an inventor of innovative technologies for the development of products for genomic analysis in research, diagnostics, and therapeutics, announced today that the U.S. Patent and Trademark Office granted the Company U.S. Patent No. 10,081,829, entitled “Detection of targeted sequence regions.” The patent covers a novel method for enriching sequence specific nucleic […]
FUJISAWA CITY, Japan & DUBLIN–GenAhead Bio Incorporated (“GenAhead”) and ERS Genomics Limited (“ERS Genomics”) announced today a non-exclusive license agreement to provide GenAhead with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology. GenAhead had its start […]
Fujisawa, Japan and Dublin, Ireland – Axcelead Drug Discovery Partners, Inc.(hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. ERS Genomics holds rights […]
Siemens Healthineers Recent FDA Clearance of the Atellica IM B•R•A•H•M•S PCT Assay Extends Access of Procalcitonin to More U.S. Laboratories WALTHAM, Mass. — Thermo Fisher Scientific Inc., today announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker that provides information on the presence and severity of bacterial infections. B·R·A·H·M·S PCT aids physicians in emergency departments […]
PISCATAWAY, NEW JERSEY – GenScript®, the world leader in the biotechnology reagent service industry, strongly denies allegations made in a research report by short seller Flaming Research. “The allegations made against our subsidiary Nanjing Legend Biotechnology Co. are inaccurate and misleading, as well as groundless and irresponsible,” said Eric Wang, GenScript’s vice president of marketing. “We […]
Santa Cruz, CA, September 2018 – SomaGenics announced today the issue of US Patent 10,041,107, a continuation of SomaGenics’ patent family entitled “Methods and Compositions for Detection of small RNAs.” The new patent broads protection for SomaGenics’ innovative, circularization-based approaches to accurately detect and quantify small RNAs, including key technologies incorporated in SomaGenics’ RealSeq® NGS […]
New license agreements for CRISPR technology from Broad Institute and ERS Genomics extend industry-leading genome editing capabilities CARLSBAD, Calif. — Thermo Fisher Scientific, Inc., the world leader in serving science, has licensed CRISPR technologies from the Broad Institute and ERS Genomics (foundational University of California IP) to bolster its genome editing intellectual property (IP) portfolio. Under the terms of […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
